NCT04181333Completed
Safety and Efficacy of Trastuzumab BS
TRASTUZUMAB BS for Intravenous Infusion 60 mg [Pfizer], TRASTUZUMAB BS for Intravenous Infusion 150 mg [Pfizer] General Investigation (Unresectable Advanced/Recurrent HER2-Overexpressing Gastric Cancer)
Source: ClinicalTrials.gov · Last updated 14 Apr 2026
Brief summary (registry, in English)
To confirm the safety and efficacy of this drug under the actual use
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 8 (actual)
- First submitted
- 7 Nov 2019
- Start date
- 9 Aug 2023
- Primary completion date
- 27 Mar 2025
- Lead sponsor
- Pfizer
- NCT number
- NCT04181333
What you commit to
- Study type: Observational
- Participants enrolled: 8
- From 9 Aug 2023 to the primary completion date, 27 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- not specified in this study
Who the study is looking for
- Patients with unresectable advanced/recurrent gastric cancer who are confirmed to have HER2 overexpression and started treatment with this drug\*
- Patients who receive this drug\* for the first time after this drug\* is launched \* Not including the biological product, HERCEPTIN, and biosimilars of HERCEPTIN other than this drug
Age in the registry: 0 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.